Stocks Showing Market Leadership: Sorrento Therapeutics Earns 93 RS Rating

Stocks Showing Market Leadership: Sorrento Therapeutics Earns 93 RS Rating

IBD's proprietary RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matches up against other publicly traded companies.